Skip to content

Study · Animal study (in vivo) · mouse · 2006

10 results

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R

American journal of physiology. Endocrinology and metabolism5 Jul 2006Cited by 12 (Europe PMC)

PMID16822960 (opens in a new tab)DOI10.1152/ajpendo.00201.2006 (opens in a new tab)PepBankPUB-16822960
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH knockout mice, CJC‑1295 given every 24 h gave normal body weight.

    In plain wordsIn GHRH knockout mice, CJC‑1295 given daily gave normal body weight.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseBody weight with daily dosing
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 microg every 24 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    GHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH knockout mice, CJC‑1295 given every 24 h gave normal body length.

    In plain wordsIn GHRH knockout mice, CJC‑1295 given daily gave normal body length.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseBody length with daily dosing
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg every 24 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    GHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH knockout mice, CJC‑1295 every 48 and 72 h gave higher body weight than placebo, without full growth normalization.

    In plain wordsIn GHRH knockout mice, CJC‑1295 every 48 or 72 hours gave higher body weight than placebo, but not fully normal growth.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseBody weight with dosing every 48 or 72 h
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Comparator
    Placebo-treated GHRHKO mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 microg every 48 h or 72 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH knockout mice, CJC‑1295 every 48 and 72 h gave higher body length than placebo, without full growth normalization.

    In plain wordsIn GHRH knockout mice, CJC‑1295 every 48 or 72 hours gave greater body length than placebo, but not fully normal growth.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseBody length with dosing every 48 or 72 h
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Comparator
    Placebo-treated GHRHKO mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg every 48 h or 72 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH knockout mice, femur and tibia length remained normal with CJC‑1295 every 24 and 48 h.

    In plain wordsIn GHRH knockout mice, thigh and shin bone length stayed normal with CJC‑1295 every 1 or 2 days.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeFemur and tibia length
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    2 microg every 24 h or 48 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Femur and tibia length remained normal in animals treated every 24 and 48 h.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH knockout mice, relative lean mass was normal in all CJC‑1295 treated groups.

    In plain wordsIn GHRH knockout mice, lean mass was normal in all groups given CJC‑1295.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeRelative lean mass
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 microg every 24 h, 48 h or 72 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Relative lean mass and subcutaneous fat mass were normal in all treated groups.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH knockout mice, relative subcutaneous fat mass was normal in all CJC‑1295 treated groups.

    In plain wordsIn GHRH knockout mice, fat under the skin was normal in all groups given CJC‑1295.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeRelative subcutaneous fat mass
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 microg every 24 h, 48 h or 72 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Relative lean mass and subcutaneous fat mass were normal in all treated groups.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In GHRH knockout mice, CJC‑1295 increased total pituitary RNA.

    In plain wordsIn GHRH knockout mice, CJC‑1295 increased the total RNA in the pituitary gland.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseTotal pituitary RNA
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg every 24 h, 48 h or 72 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In GHRH knockout mice, CJC‑1295 increased pituitary GH mRNA.

    In plain wordsIn GHRH knockout mice, CJC‑1295 increased growth hormone mRNA in the pituitary gland.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreasePituitary GH mRNA
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg every 24 h, 48 h or 72 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In GHRH knockout mice, immunohistochemistry images confirmed that CJC‑1295 caused proliferation of pituitary somatotroph cells.

    In plain wordsIn GHRH knockout mice, tissue staining confirmed that CJC‑1295 increased the number of growth hormone-producing pituitary cells.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseSomatotroph cell proliferation
    Study

    mousen: not reported in source

    GHRH knockout (GHRHKO) mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg every 24 h, 48 h or 72 h · 5 weeksAs given in this study (mouse).

    Source sentences

    Summary
    CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images.
    1 context sentence
    Summary · context
    Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.